Samsung Breaks New Ground with Mass Production of Industry’s Smallest 0.64μm-pixel Mobile Image Sensor
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the industry’s first 0.64-micrometer (μm)-pixel image sensor, the 50-megapixel (Mp) Samsung ISOCELL JN1. Equipped with the latest pixel technologies such as enhanced ISOCELL 2.0, Smart-ISO and Double Super PDAF, the JN1 can capture more vivid images on the industry’s smallest 50Mp mobile sensor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005350/en/
Industry’s Smallest 0.64μm-Pixel Mobile Image Sensor, Samsung ISOCELL JN1 (Photo: Business Wire)
“Samsung’s advanced pixel technologies have once again pushed boundaries with the utmost precision to develop an image sensor with the industry’s smallest pixel size, yet with powerful performance. The new ISOCELL JN1 at 0.64μm will be able to equip tomorrow’s sleekest smartphones with ultra-high resolution mobile photographs,” said Duckhyun Chang, executive vice president of the sensor business at Samsung Electronics. “As we drive our commitment to innovation in pixel technologies, we will continue to bring a wide range of mobile image sensor offerings to the market.”
A new addition to Samsung’s high-resolution image sensor lineup, the JN1 employs ISOCELL 2.0 technology with added enhancements that improve light sensitivity by around 16-percent. For low-light environments, the sensor utilizes Samsung’s four-to-one pixel binning technology, Tetrapixel, which merges four adjacent 0.64μm-pixels into one big 1.28μm-pixel to quadruple light sensitivity for brighter 12.5Mp photographs.
With such advanced technologies all embedded in a small 1/2.76-inch optical format, the ISOCELL JN1 is the most versatile image sensor yet from Samsung. Through close collaboration with ecosystem partners, the JN1 is compatible with existing 1/2.8-inch products, allowing the sensor to be used for front-facing, ultra-wide or telephoto cameras, in addition to standard wide camera options. This means that users can take highly detailed selfies or group pictures in an amazing 50Mp resolution, as well as high-resolution video at up to 4K and high-zoom ratios. The smaller sensor can also reduce the height of the camera module by around 10-percent, minimizing the camera bulge for slimmer and more streamlined designs in next-generation smartphones.
For enhanced dynamic range, the ISOCELL JN1 comes with Smart-ISO, a technology that changes the conversion gain based on the environment’s illumination level. Smart-ISO uses Low ISO mode in bright settings to retain detail in the highlights, and High ISO in low-lit environments to reduce readout noise and generate excellent low-light performance. Using Smart-ISO, the JN1 also offers inter-scene HDR in mixed-light settings for optimum exposure levels derived from two separate readouts, from Low and High ISOs, that are merged to create a final image.
For faster auto-focus, the ISOCELL JN1 integrates improved Double Super PD. The previous Super PD technology used specially designed oval-shaped micro-lenses over two adjacent pixels arranged side by side to detect phases. Double Super PD features twice the density of pixels (1/16) used for phase detection than Super PD (1/32), enabling the same auto-focus performance even in environments with about 60-percent less illumination levels. For smooth crystal-clear videos, the image sensor supports up to 4K resolution video recording at 60 frames-per-second (fps) or full HD at 240fps.
The Samsung ISOCELL JN1 is currently in mass production.
* Editor's Note: Actual performance may vary depending on device and user environment.
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005350/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom